Legend Biotech Corporation has released its first quarter 2025 financial results, highlighting several key figures and developments. The company's net trade sales for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) reached approximately $369 million. The net loss for the three months ended March 31, 2025, was reported at $100.9 million, an increase from the $59.8 million net loss recorded during the same period in 2024. However, the adjusted net loss for the first quarter of 2025 was $27.0 million, showing a significant improvement compared to the adjusted net loss of $85.3 million in the first quarter of 2024. Legend Biotech's cash and cash equivalents, along with time deposits, stood at $1.0 billion as of March 31, 2025. This financial position is expected to sustain the company into the second quarter of 2026. License revenue for the first quarter of 2025 was $9.3 million, down from $12.2 million in the previous year, primarily due to the timing of activities related to the Novartis License Agreement for the LB2102 clinical trial. In terms of operational updates, Legend Biotech commenced clinical production of CARVYKTI® at the Tech Lane facility. Additionally, the company received a positive CHMP opinion to include a statistically significant improvement in overall survival from the CARTITUDE-4 study in the CARVYKTI® label. Furthermore, CARVYKTI® received approval from Australia's TGA for use in second-line plus settings for multiple myeloma patients.